Elevated Plasma Levels of Interleukin-1 Receptor Antagonist and Interleukin-10 in Patients with Acute Myocardial Infarction
- 1 March 1997
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 17 (3) , 145-150
- https://doi.org/10.1089/jir.1997.17.145
Abstract
The study was undertaken to measure plasma interleukin-1 (IL-1) receptor antagonist and IL-10 concentrations in patients with acute myocardial infarction and to analyze their relationship to the hemodynamics, severity, and prognosis of myocardial infarction in its acute stages. We attempted to define the kinetics of IL-1 receptor antagonist and IL-10 in patients with acute myocardial infarction (n = 34, age 42—91 years, mean 68 years). Plasma IL-1 receptor antagonist and IL-10. levels were measured by enzyme-linked immunosorbent assay. Patients in group A (n = 17) had uncomplicated acute myocardial infarction (Killip class I). Patients in group B (n = 17) had severe acute myocardial infarction (Killip class II, III, or IV). Peak II-1 receptor antagonist and IL-10 levels in group B were significantly higher (p < 0.05) than those of group A. In group B, the peak IL-1 receptor antagonist levels were significantly correlated with white blood cell counts (r = 0.63, p = 0.006), pulmonary capillary wedge pressure (r = 0.78, p = 0.0002), and cardiac index (r = —0.51, p = 0.04). Peak IL-10 levels were significantly correlated with white blood cell counts (r = 0.60, p = 0.01), the pulmonary wedge pressure (r = 0.73, p = 0.0008), and cardiac index (r = —0.50,p = 0.04). Moreover, a significant correlation was found between the peak IL-1 receptor antagonist and IL-10 levels (r = 0.91, p < 0.0001). The peak IL-1 receptor antagonist levels in nonsurvivors (n = 13) were significantly higher (p < 0.01) than those in survivors (n = 21). The plasma IL-1 receptor antagonist and IL-10 levels were closely correlated with the severity of hemodynamics in acute myocardial infarction and with the clinical status of patients with severe acute myocardial infarction. Results suggest that plasma IL-1 receptor antagonist and IL-10 can serve as prognostic indicators in cases of sever acute myocardial infarction.Keywords
This publication has 11 references indexed in Scilit:
- Levels of T-lymphocyte subpopulations, interleukin-1β, and soluble interleukin-2 receptor in acute myocardial infarctionAmerican Heart Journal, 1994
- Cytokines in Acute Myocardial InfarctionJournal of Cardiovascular Pharmacology, 1994
- Elevated plasma interleukin-6 levels in patients with acute myocardial infarctionAmerican Heart Journal, 1993
- Production of interleukin-1-receptor antagonist during experimental endotoxaemiaThe Lancet, 1991
- Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.Journal of Clinical Investigation, 1991
- cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.Proceedings of the National Academy of Sciences, 1991
- A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbitsThe FASEB Journal, 1991
- Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin FeverThe Journal of Infectious Diseases, 1990
- Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.The Journal of Experimental Medicine, 1988
- Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog.Circulation, 1983